Novocure Limited Press Releases http://novocure2017ir.q4web.com/generated by Q4Sat, 04 Apr 2026 06:25:49 -0400Copyright Q4 Inc. All rights reserved.Novocure to Report First Quarter 2026 Financial Results9dc59891-01ca-429d-bc80-a0522d0fa899http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-to-Report-First-Quarter-2026-Financial-Results/default.aspxWed, 01 Apr 2026 07:00:00 -0400Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer7781b40b-2cf1-49b7-9be5-b26d7f2ab27ahttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Announces-Positive-Topline-Results-from-Phase-2-PANOVA-4-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Metastatic-Pancreatic-Cancer/default.aspxThu, 26 Mar 2026 07:00:00 -0400Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancerce0670cf-7722-4331-be96-8208232b4d65http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Announces-Optune-Lua-Receives-Reimbursement-Approval-in-Japan-for-the-Treatment-of-Non-Small-Cell-Lung-Cancer/default.aspxMon, 02 Mar 2026 07:00:00 -0500Novocure to Participate in 2026 Leerink Global Healthcare Conference963cdb08-2749-4227-b6eb-172ece7383c6http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-to-Participate-in-2026-Leerink-Global-Healthcare-Conference/default.aspxFri, 27 Feb 2026 16:30:00 -0500Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Updatef58cb636-e2a3-47d8-8598-963b659132aehttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Company-Update/default.aspxThu, 26 Feb 2026 07:00:00 -0500Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)584f11a6-a15c-4a53-ae1e-5682d158108chttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Tumor-Treating-Fields-TTFields-Therapy-to-be-Covered-for-Patients-with-Newly-Diagnosed-Glioblastoma-Through-British-Columbia-Cancer-BC-Cancer/default.aspxTue, 24 Feb 2026 07:00:00 -0500U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancerf7ddcd51-76f2-4846-ab50-b14e91fb9f4ahttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/U-S--FDA-Approves-Novocures-Optune-Pax-for-the-Treatment-of-Locally-Advanced-Pancreatic-Cancer/default.aspxWed, 11 Feb 2026 17:54:00 -0500Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Updatecb63abb8-1974-4593-a055-86935b1e1a0dhttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Announces-Preliminary-Full-Year-and-Fourth-Quarter-2025-Performance-and-Provides-Company-Update/default.aspxMon, 12 Jan 2026 07:00:00 -0500Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference60b3f279-aa4c-4535-a0e0-3e643185ad65http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2025/Novocure-to-Present-at-44th-Annual-J-P--Morgan-Healthcare-Conference/default.aspxMon, 22 Dec 2025 07:00:00 -0500Novocure Appoints Company President Frank Leonard as Chief Executive Officer67a7d9dd-b3a1-4ca9-bf07-e8c10c091e90http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2025/Novocure-Appoints-Company-President-Frank-Leonard-as-Chief-Executive-Officer/default.aspxMon, 01 Dec 2025 07:00:00 -0500